{rfName}
Se

Indexed in

License and use

Citations

56

Altmetrics

Grant support

This work was supported by Ministerio de Economia y Competitividad and Instituto de Salud Carlos III, Fondo Investigacion Sanitaria (grant numbers PI15/00531, SAF2015-66515-R and RTC-2015-4184-1), the European Regional Development Fund (ERDF) 'Una manera de hacer Europa', Fundacio La Marato TV3 (grant numbers 20153030 and 20153031), the Catalonian Society of Cardiology SCC_ROCHE2015_001 (SAP Code: DN040578) and Siemens Healthcare 11/425.

Analysis of institutional authors

Caldentey GAuthorDe Frutos, PgAuthorCristóbal HAuthorGarabito MAuthorBerruezo AAuthorBosch XAuthorSan Antonio RAuthorFlores-Umanzor EAuthorPerea RjAuthorDe Caralt TmAuthorRodriguez JAuthor

Share

Publications
>
Article

Serum levels of Growth Arrest-Specific 6 protein and soluble AXL in patients with ST-segment elevation myocardial infarction.

Publicated to:European Heart Journal-Acute Cardiovascular Care. 8 (8): 708-716 - 2019-12-01 8(8), DOI: 10.1177/2048872617740833

Authors: Caldentey, Guillem; Garcia De Frutos, Pablo; Cristobal, Helena; Garabito, Manel; Berruezo, Antonio; Bosch, Xavier; San Antonio, Rodolfo; Flores-Umanzor, Eduardo; Perea, Rosario J; De Caralt, Teresa M; Rodriguez, Jany; Ortiz-Perez, Jose T

Affiliations

1 Institut Clínic Cardiovascular, Hospital Clínic Barcelona, Spain. - Author
2 Department of Cell Death and Proliferation, IIBB-CSIC and IDIBAPS, Barcelona, Spain. - Author
3 Institut d'investigacions Biomèdiques August Pi i Sunyer, IDIBAPS, University of Barcelona, Spain. - Author
4 Centre de Diagnòstic per la Imatge, Hospital Clínic Barcelona, Spain. - Author
Hosp Clin Barcelona, Ctr Diagnost Imatge, Barcelona, Spain - Author
Hosp Clin Barcelona, Inst Clin Cardiovasc, Barcelona, Spain - Author
IDIBAPS, Barcelona, Spain - Author
IIBB CSIC, Dept Cell Death & Proliferat, Barcelona, Spain - Author
Univ Barcelona, IDIBAPS, Barcelona, Spain - Author
See more

Abstract

Serum soluble AXL (sAXL) and its ligand, Growth Arrest-Specific 6 protein (GAS6), intervene in tissue repair processes. AXL is increased in end-stage heart failure, but the role of GAS6 and sAXL in ST-segment elevation myocardial infarction (STEMI) is unknown.To study the association of sAXL and GAS6 acutely and six months following STEMI with heart failure and left ventricular remodelling.GAS6 and sAXL were measured by enzyme-linked immunosorbent assay at one day, seven days and six months in 227 STEMI patients and 20 controls. Contrast-enhanced magnetic resonance was performed during admission and at six months to measure infarct size and left ventricular function.GAS6, but not sAXL, levels during admission were significantly lower in STEMI than in controls. AXL increased progressively over time ( p<0.01), while GAS6 increased only from day 7. GAS6 or sAXL did not correlate with brain natriuretic peptide or infarct size. However, patients with heart failure (Killip >1) had higher values of sAXL at day 1 (48.9±11.9 vs. 44.0±10.7 ng/ml; p<0.05) and at six months (63.3±15.4 vs. 55.9±13.7 ng/ml; p<0.05). GAS6 levels were not different among subjects with heart failure or left ventricular remodelling. By multivariate analysis including infarct size, Killip class and sAXL at seven days, only the last two were independent predictors of left ventricular remodelling (odds ratio 2.24 (95% confidence interval: 1.08-4.63) and odds ratio 1.04 (95% confidence interval: 1.00-1.08) respectively).sAXL levels increased following STEMI. Patients with heart failure and left ventricular remodelling have higher sAXL levels acutely and at six month follow-up. These findings suggest a potential role of the GAS6-AXL system in the pathophysiology of left ventricular remodelling following STEMI.

Keywords

AdultAgedArticleAxl protein, humanAxl receptor tyrosine kinaseBeta adrenergic receptor blocking agentBiological markerBlood samplingBrain natriuretic peptideC reactive proteinCalcificationCaptoprilCardiac remodellingCardiovascular magnetic resonanceControlled studyDiastolic blood pressureElectrocardiographyEnalaprilEnzyme linked immunosorbent assayExpressionFemaleFollow upFollow-up studiesGadodiamideGalectin-3Gas6Gas6 proteinGeneGrowth arrest specific protein 6Growth arrest-specific protein 6Heart failureHeart infarction sizeHeart left ventricle ejection fractionHeart left ventricle enddiastolic volumeHeart left ventricle endsystolic volumeHeart left ventricle functionHeart ventricle remodelingHospital admissionHospitalizationHumanHumansInflammationIntercellular signaling peptides and proteinsMagnetic resonance imagingMajor clinical studyMaleMiddle agedMyocardial infarctionNatriuretic peptide, brainNuclear magnetic resonance imagingPathophysiologyPercutaneous coronary interventionPriority journalProtein axlProto-oncogene proteinsReceptor protein-tyrosine kinasesReceptor tyrosine kinaseSmooth-muscle-cellsSt elevation myocardial infarctionSt segment elevation myocardial infarctionSystolic blood pressureTam receptorsTnf-alphaTroponin iUnclassified drugVentricular remodeling

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal European Heart Journal-Acute Cardiovascular Care due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2019, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Medicine (Miscellaneous). Notably, the journal is positioned above the 90th percentile.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 5.1, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Jun 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-06-16, the following number of citations:

  • WoS: 20
  • Scopus: 22
  • Europe PMC: 14
  • OpenCitations: 20

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-06-16:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 32.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 32 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 1.
  • The number of mentions on the social network X (formerly Twitter): 1 (Altmetric).

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Ortiz Pérez, José Tomás) and Last Author (Ortiz-Pérez JT).

the author responsible for correspondence tasks has been Ortiz-Pérez JT.